CIPLA's weekly performance was lackluster, with a return of -0.67% and a Sharpe Ratio of -0.15, indicating poor risk-adjusted returns. The stock's volatility was moderate at 17.09%, which is higher than SUNPHARMA's but lower than DIVISLAB's. Compared to its peers, CIPLA underperformed SUNPHARMA and DIVISLAB but outperformed GRASIM. The stock's Max Drawdown of -1.73% suggests a relatively risky week.

[Volatility: 17.09%]